MX2009001342A - Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion. - Google Patents

Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.

Info

Publication number
MX2009001342A
MX2009001342A MX2009001342A MX2009001342A MX2009001342A MX 2009001342 A MX2009001342 A MX 2009001342A MX 2009001342 A MX2009001342 A MX 2009001342A MX 2009001342 A MX2009001342 A MX 2009001342A MX 2009001342 A MX2009001342 A MX 2009001342A
Authority
MX
Mexico
Prior art keywords
treatment
methods
radiation enteritis
present
enteritis
Prior art date
Application number
MX2009001342A
Other languages
English (en)
Inventor
Doug Bettenhausen
Christopher Jahraus
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of MX2009001342A publication Critical patent/MX2009001342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La presente invención proporciona un método novedoso para prevenir, mejorar y/o tratar enteritis inducida por terapias abdominopélvicas. La presente invención también se relaciona con el tratamiento profiláctico de la diarrea del viajero.
MX2009001342A 2006-08-02 2007-08-02 Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion. MX2009001342A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83527306P 2006-08-02 2006-08-02
US85029906P 2006-10-06 2006-10-06
PCT/US2007/017379 WO2008016708A2 (en) 2006-08-02 2007-08-02 Methods for treatment of radiation enteritis

Publications (1)

Publication Number Publication Date
MX2009001342A true MX2009001342A (es) 2009-08-31

Family

ID=38997731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001342A MX2009001342A (es) 2006-08-02 2007-08-02 Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.

Country Status (17)

Country Link
EP (1) EP2054066B1 (es)
JP (3) JP5844961B2 (es)
KR (2) KR20150132214A (es)
CN (1) CN104382900A (es)
AU (1) AU2007281413B2 (es)
BR (1) BRPI0714724A8 (es)
CA (1) CA2659874C (es)
DK (1) DK2054066T3 (es)
ES (1) ES2538478T3 (es)
HK (1) HK1130199A1 (es)
HU (1) HUE025306T2 (es)
IL (1) IL196843A (es)
MX (1) MX2009001342A (es)
PL (1) PL2054066T3 (es)
PT (1) PT2054066E (es)
SI (1) SI2054066T1 (es)
WO (1) WO2008016708A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP5844961B2 (ja) * 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
HUE065491T2 (hu) 2008-10-02 2024-05-28 Salix Pharmaceuticals Ltd A hepatikus enkefalopátia kezelése rifaximin alkalmazásával
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
US20110294726A1 (en) * 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN105477624A (zh) * 2015-12-16 2016-04-13 官键 一种用于治疗放射性直肠炎的药物组合物
RU2618452C1 (ru) * 2015-12-28 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования энтерита

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
JP5844961B2 (ja) * 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法

Also Published As

Publication number Publication date
AU2007281413A1 (en) 2008-02-07
HK1130199A1 (en) 2009-12-24
PT2054066E (pt) 2015-07-16
JP2016028079A (ja) 2016-02-25
WO2008016708A2 (en) 2008-02-07
IL196843A0 (en) 2009-11-18
SI2054066T1 (sl) 2015-08-31
CA2659874C (en) 2016-10-11
BRPI0714724A8 (pt) 2018-04-10
CN104382900A (zh) 2015-03-04
BRPI0714724A2 (pt) 2015-07-07
KR20150132214A (ko) 2015-11-25
EP2054066A2 (en) 2009-05-06
JP2009545602A (ja) 2009-12-24
EP2054066A4 (en) 2011-01-05
ES2538478T3 (es) 2015-06-22
JP5844961B2 (ja) 2016-01-20
IL196843A (en) 2016-03-31
DK2054066T3 (en) 2015-06-08
HUE025306T2 (hu) 2016-01-28
EP2054066B1 (en) 2015-04-15
JP2013227350A (ja) 2013-11-07
PL2054066T3 (pl) 2015-12-31
JP5993074B2 (ja) 2016-09-14
WO2008016708A3 (en) 2008-06-19
AU2007281413B2 (en) 2013-10-31
KR20090047490A (ko) 2009-05-12
CA2659874A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
MX2009001342A (es) Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
NL301145I1 (es)
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
TW200716624A (en) Compounds for modulating TRPV3 function
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2007092622A3 (en) Compositions and methods for treating bone
WO2006042249A3 (en) Methods and compositions for treating migraine pain
HK1096298A1 (en) Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
WO2008156685A3 (en) Tendon stem cells
TW200716088A (en) Formulations and methods for treating amyloidosis
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
EP2513336A4 (en) METHOD FOR CHARACTERIZING THE IMMUNE FUNCTION OF EX VIVO INDUCTIVE HOST OF OFFENSIVE AND DEFENSIVE IMMUNE MARKERS
TW200507840A (en) Method of treating multiple myeloma
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
ZA200609220B (en) Method of treating dry eye disorders and uveitis
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
EP4397752A3 (en) Methods for obtaining induced smooth muscle cells
MX2009005400A (es) Metodo para el diagnostico y tratamiento del glioma.
WO2003106656A3 (en) SINGLE-DOMAIN COMPOUNDS ASSOCIATED WITH TDF AND THE LIKE THEREOF
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
WO2004098519A3 (en) Ginkgo biloba extract as a treatment for therapeutic­ induced neurotoxicity
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia